ENT DISORDER TREATMENT MARKET ANALYSIS

ENT Disorder Treatment Market, by Treatment Type (Devices (Hearing Aid Devices, Voice Prosthesis, Nasal Splints, Hearing Implants and Others) and Drug Type (Antibiotics, Antihistamines, Steroids, Anti-inflammatory Drugs, Others)), by Organ Type (Ear, Nose, and Throat), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, Home Care Settings, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022
Code : CMI1326
Pages :161
Formats :
Excel and PDF
Industry : Medical Devices

Ent Disorder Treatment MarketSize and Trends

The global ENT disorder treatment market is estimated to be valued at US$ 11,219.19 million in 2022 and is expected to exhibit a CAGR of 3.3% during the forecast period (2022-2030).

Increasing air and noise pollution is expected to aid in growth of ENT disorder treatment market

One of major factors leading to rise in number of ENT diseases is increasing air and noise pollution as well as bacterial concentration in the environment leading to various infections. According to the World Health Organization, 2017, around 40% of the European population is exposed to road traffic noise levels exceeding 55 decibels, leading to chronic hearing diseases such as loss of hearing, and earache. Moreover, air pollution can lead to throat infections as well as nasal infections leading to sinusitis and other disorders. According to the Centers of Disease Control and Prevention (CDC) 2017, around 25% of all hearing loss cases in Europe are due to noise and sound caused due to environmental pollution termed as Noise Induced Hearing Loss (NIHL). Moreover, excessive smoking can also lead to throat diseases leading to cancer.

New development of antibiotics and increasing approvals of antibiotics would provide opportunities for the market growth over the forecast years

Increasing new development and approvals of antibiotics is expected to drive the global ENT disorder treatment market over the forecast period. For instance, in August 2019, The U.S. Food and Drug Administration approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. This new drug provided another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease. Lefamulin is a semisynthetic pleuromutilin antibiotic for community-acquired bacterial pneumonia.